Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.

The study found that weight regain varied with follow-up, with participants experiencing weight regain at eight, 12, and 20 ...

New medicines have made weight loss easier than ever. But if you also want health and happiness, make these seven psychology ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance ...

New research reveals weight-loss drugs help during treatment but weight returns rapidly after stopping. Experts urge ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...

As anyone who prescribes GLP-1 therapies is surely aware, access remains a significant barrier to treatment due to lack of insurance coverage and, at times, lack of medication supply. In these ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

In a recent study published in Life Metabolism, researchers at Fudan University report that even after stopping the anti-obesity drug tirzepatide, ...

Experts say there’s no evidence GLP-1s can be absorbed through the skin — and these patches don’t contain the FDA-approved ...